(Q40347818)

19 September 2017

title

TGF-beta, T-cell tolerance and immunotherapy of autoimmune diseases and cancer (English)

1 reference

19 September 2017

1 reference

2

Richard A Flavell

1 reference

19 September 2017

Ming O Li

1

1 reference

19 September 2017

publication date

1 March 2006

1 reference

Expert Review of Clinical Immunology

19 September 2017

published in

1 reference

19 September 2017

volume

2

1 reference

19 September 2017

issue

2

1 reference

19 September 2017

page(s)

257-265

1 reference

Cellular and genetic mechanisms of self tolerance and autoimmunity

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Regulation of immunity by self-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Genetic analysis of the mammalian transforming growth factor-beta superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Role of transforming growth factor beta in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Genealogy, expression, and cellular function of transforming growth factor-β

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Making sense of latent TGFbeta activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Thrombospondin-1 is a major activator of TGF-beta1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

TGF-beta signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Mechanisms of TGF-beta signaling from cell membrane to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Transcriptional control by the TGF-beta/Smad signaling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Conditional inactivation of the TGF-beta type II receptor using Cre:Lox

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Transforming growth factor-beta in T-cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Uncoupling of promitogenic and antiapoptotic functions of IL-2 by Smad-dependent TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Design of effective immunotherapy for human autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Oral Tolerance in the Treatment of Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Does the immune system see tumors as foreign or self?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

The three Es of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Reversal of tumor-induced immunosuppression by TGF-beta inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

TGF-beta signaling: positive and negative effects on tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Development of TGF-beta signalling inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Cancer immunotherapy: a treatment for the masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

Cutting Edge: TGF- Signaling Is Required for the In Vivo Expansion and Immunosuppressive Capacity of Regulatory CD4+CD25+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.2.257

21 January 2018

Identifiers

DOI

10.1586/1744666X.2.2.257

1 reference

19 September 2017

1 reference